Kitazato

Kitazato OCF/Debt

The Operating Cash Flow to Debt Ratio of Kitazato (368A.T) as of Nov 11, 2026 is 2,963.03 %. In the previous year, Operating Cash Flow to Debt Ratio was 2,727.88 % — a change of 8.62% (higher).

OCF/Debt

2,963.03 %

YoY

8.62%

Last updated:

Operating Cash Flow to Debt Ratio of Kitazato is 2025 2,963.03 % . Operating Cash Flow to Debt Ratio of Kitazato was 2024 2,727.88 % . It decreases by 8.62% higher compared to the previous year.

The Kitazato OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2023
1,601.50 JPY
Jan 1, 2024
2,727.88 JPY
Jan 1, 2025
2,963.03 JPY
The Kitazato OCF/Debt history
YEAROCF/DebtYoY
2,963.03 %+8.62%
2,727.88 %+70.33%
1,601.50 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Kitazato Stock analysis

What does Kitazato do? Kitazato Corp manufactures and sells medical devices, reagents, and related products for infertility treatment, specializing in reproductive engineering technology for artificial insemination, in vitro fertilization, and cell cryopreservation. The company produces consumables such as medical equipment and reagents used in in vitro fertilization and intracytoplasmic sperm injection, including media, cryo devices, medical devices, and micro tools. Kitazato Corp distributes its products globally, serving markets in Japan, Europe, the United States, China, and India, with a focus on research reagents and medical equipment for infertility treatment. The firm also manufactures and sells medical equipment parts, provides genetic testing services, and offers medical equipment for the elderly. Additionally, Kitazato Corp engages in market research, acquisition of local licenses, and contract management of living cells, expanding its reach into regenerative medicine and related fields. These services and products target healthcare providers, fertility clinics, and research institutions worldwide. Kitazato Corp's revenue streams include the sale of consumables, medical devices, and reagents, as well as genetic testing and contract management services. The company's global distribution network supports sales across key regions, with a strong emphasis on infertility treatment solutions and regenerative medicine technologies. Kitazato is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kitazato stock

Operating Cash Flow to Debt Ratio of Kitazato is 2,963.03 % in 2025.

Operating Cash Flow to Debt Ratio of Kitazato changed from 2,727.88 % to 2,963.03 %, representing a 8.62% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio Kitazato since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's Kitazato with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Kitazato

All Key Metrics — Kitazato